- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Reasons for attending the AAD meeting | AAD 2024
John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.
John Barbieri, M.D., MBA, is one of the more 17,000 dermatologists and others attending the American Academy of Dermatology’s annual meeting this weekend in San Diego.
Barbieri, an assistant professor at Harvard Medical School, says he is looking forward to the fresh troves of data and the connecting with colleagues.
“I love seeing the new trial data as it comes out, and the late breaking research sessions are a good place to find those,” Barbieri said in a recent interview. “I also find that AAD is a great time to connect with colleagues. I think that's one of the best parts of this meeting is being able to see all of our colleagues in dermatology to think about how we can collaborate, to think about how we can move the field forward together.”
Barbieri specializes in inflammatory skin disease such as acne, rosacea, psoriasis and atopic dermatitis. He is the director of the Advanced Acne Therapeutics Clinic at the Harvard-affiliated Brigham and Women’s Hospital in Boston and is the co-chair of the academy’s acne guidelines work group.
He is speaking at four sessions at the meeting, which started today and ends on Tuesday. The sessions he is speaking are titled Great Care for Common Conditions: Combining Evidence and Cost Effectiveness; JAAD [Journal of the American Academy of Dermatology] game changers; Controversies in Acne and Rosacea; and Translating Evidence Into Practice: Acne Guidelines and Beyond.
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More
Microneedling Combined with Other Vitiligo Therapies Offers Promising Treatment for Skin Disease
April 10th 2024Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.
Read More
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
